October 2026 Biotech Catalysts to Watch
FDA decisions and clinical trial readouts expected in October 2026, each marked with what — if anything — a primary source confirms about it.
No date on this page has been confirmed against a primary source. Unsourced entries are AI-drafted from public information and can be wrong about whether an event is still upcoming; they are listed separately and show the expected window only. Verify against the FDA, the company, or ClinicalTrials.gov before acting on any of them. 2 of 6 link to the ClinicalTrials.gov record for the program behind them — the registry confirms that the program exists, not the date.
6 catalysts shown
Potential accelerated approval filing for NTLA-2002 in HAE
NTLA-2002 · Hereditary angioedema (HAE)
Program confirmed on ClinicalTrials.gov · 2026-09-05 · the date itself is unverified
Tight against cash. Cash reaches roughly Q4 2027 on the disclosed figures, about 4 quarters past this Q4 2026 catalyst. A disappointing result would leave little room to fund what comes next.
Sponsor record: 2 of 6 late-stage studies registered by Intellia Therapeutics were stopped early. Trials stop for many reasons — see the company profile for each one.
Why it matters
Intellia is expected to file for accelerated approval of NTLA-2002, a CRISPR-based therapy for hereditary angioedema, a rare genetic disorder causing severe swelling attacks. This filing is based on promising Phase 1/2 data showing durable reduction in attacks. If approved, it would be the first CRISPR therapy for a non-blood disease, marking a major milestone.
The filing itself is a catalyst, as it confirms the regulatory path. If the FDA accepts the application, Intellia's stock could rise. The market will also look for any updates on the rolling submission. Approval is not guaranteed, but the data has been strong. A positive outcome would validate CRISPR's potential beyond rare diseases.
AI-drafted context, not individually reviewed.
Phase 3 data for suzetrigine in diabetic peripheral neuropathy
Suzetrigine · Diabetic peripheral neuropathy (DPN)
Program confirmed on ClinicalTrials.gov · 2026-09-09 · the date itself is unverified
Sponsor record: 17 of 156 late-stage studies registered by Vertex Pharmaceuticals were stopped early. Trials stop for many reasons — see the company profile for each one.
Why it matters
Vertex is reporting Phase 3 data for suzetrigine, a non-opioid pain drug, in diabetic peripheral neuropathy. This is a pivotal readout that could provide a new treatment for chronic pain without the risks of opioids. The drug targets a specific sodium channel, and positive results would be a major advance in pain management.
If the trial shows significant pain relief and good safety, Vertex's stock could rise, as it would open a massive market. The market will also look for any adverse events, especially cardiac. Failure would be a setback, but Vertex has other programs. Given the opioid crisis, a non-addictive painkiller is highly sought after.
AI-drafted context, not individually reviewed.
Unconfirmed watchlist
No primary source has been found for these yet. They are AI-drafted from public information, shown with the expected window rather than a day, and may already have happened or moved. Treat them as prompts to check the company's guidance, not as dates.
Phase 3 data for NBI-1065845 in MDD (first trial)
NBI-1065845 · Major Depressive Disorder (MDD)
Unverified — date is AI-generated and has not been checked against a primary source.
Sponsor record: 10 of 59 late-stage studies registered by Neurocrine Biosciences were stopped early. Trials stop for many reasons — see the company profile for each one.
Why it matters
Neurocrine is reporting Phase 3 data for NBI-1065845, an investigational drug for major depressive disorder. This is the first of two pivotal trials, and positive results would support a new treatment option for the millions of patients who don't respond to existing antidepressants. The drug works by a novel mechanism, which could differentiate it from current therapies.
If the trial meets its primary endpoint of reducing depression scores, Neurocrine's stock could jump, as it would validate a new mechanism and expand its CNS portfolio. Failure would be a major blow. The market will also assess safety, particularly any psychiatric side effects. Given the high unmet need, even a modest effect could be commercially successful, but the FDA will require consistent results across trials.
AI-drafted context, not individually reviewed.
Phase 3 data for ONC-392 in NSCLC
ONC-392 · Non-small cell lung cancer (NSCLC)
Unverified — date is AI-generated and has not been checked against a primary source.
Sponsor record: 7 of 57 late-stage studies registered by BioNTech were stopped early. Trials stop for many reasons — see the company profile for each one.
Why it matters
BioNTech is releasing Phase 3 data for ONC-392, an anti-CTLA-4 antibody, in non-small cell lung cancer. This is a pivotal readout that could position ONC-392 as a potential new treatment option for NSCLC, a large market. The data will show if the drug improves survival compared to standard of care, and positive results could significantly boost BioNTech's oncology pipeline beyond its COVID vaccine franchise.
If the trial meets its primary endpoint of overall survival, expect a significant stock rally as ONC-392 could become a major revenue driver. If it fails, shares could drop sharply. The market will also look at safety data and any subgroup analyses. Given the high unmet need in NSCLC, even modest efficacy could be viewed positively, but a clear benefit over existing therapies is needed for a strong commercial launch.
AI-drafted context, not individually reviewed.
Panorama Phase 3 topline data for DT120 ODT in GAD
DT120 ODT (formerly MM120) · Generalized anxiety disorder (GAD)
Unverified — date is AI-generated and has not been checked against a primary source.
Why it matters
MindMed is reporting topline results from its Phase 3 Panorama trial of MM120 (lysergide) for generalized anxiety disorder. This is a pivotal study that could lead to the first psychedelic-based treatment for GAD. The trial compares MM120 to placebo, and positive results would validate the therapeutic potential of psychedelics in mental health, a field with high interest but also high regulatory hurdles.
A positive outcome with significant improvement on the Hamilton Anxiety Scale and good safety could send MindMed's stock soaring, as it would be a major milestone for psychedelic medicine. Failure would be a severe setback. The market will also watch for durability of effect and any adverse events. Given the high prevalence of GAD, even a modest effect size could be commercially viable, but the FDA will require robust evidence.
AI-drafted context, not individually reviewed.
Phase 2 data for NBI-1117568 in Bipolar I Disorder
NBI-1117568 · Bipolar I Disorder
Unverified — date is AI-generated and has not been checked against a primary source.
Sponsor record: 10 of 59 late-stage studies registered by Neurocrine Biosciences were stopped early. Trials stop for many reasons — see the company profile for each one.
Why it matters
Neurocrine is reporting Phase 2 data for NBI-1117568, a muscarinic receptor agonist, in bipolar I disorder. This is an early-stage readout, but it could provide a new treatment option for bipolar depression. The data will show efficacy and safety, and positive results would support further development.
If the drug shows significant improvement in depression scores and is well-tolerated, Neurocrine's stock could see a modest bump. Failure would be a setback but not catastrophic. The market will compare to existing treatments like lithium and atypical antipsychotics. Given the need for better options, positive data could be meaningful.
AI-drafted context, not individually reviewed.
Market context
This month's list is deliberately short. Phase 1 updates, a conference 'update' and an enrollment milestone were removed on 2026-10-02 rather than left to pad the count. Two remaining entries link to the ClinicalTrials.gov record for the program behind them; the rest are unconfirmed and are shown with the guided window only, not a day. MindMed's Panorama readout also appeared on the September calendar; it is kept here with its half-year window because no source has dated it. Before trading around any of these, check the company's own most recent guidance: sponsors move readout windows often, and nothing on this page confirms a date.
Sponsored
Trade upcoming biotech catalysts commission-free on WebullAffiliate link — we may earn a commission at no cost to you
Want one of these readouts explained in writing?
Name a catalyst from this calendar and get a written breakdown of what the trial actually measures, what success and failure look like, and where the endpoint, safety, and financing risk sits — in 3 business days, for $249.
Get the free October 2026 catalyst briefing
Receive the next weekly briefing with the biggest upcoming catalysts, date changes, and plain-English context.
Free weekly biotech briefing. No spam. We only use this address for the briefing. By subscribing, you agree to our Privacy Policy and Terms.
No financial advice. Educational research only. Affiliate links may earn compensation.